

1 **Original Research**

2 **Dereje Leta *et al*** (<https://orcid.org/0000-0001-9121-3797>*lang=en*)

3 **Effect of Heat inactivation and bulk lysis on Real-Time Reverse Transcription PCR**

4 **Detection of the SARS-COV-2: An Experimental Study**

5 **Dereje Leta¹, Gadissa Gutema¹, Gebremedhin Gebremichael Hagos¹, Regasa Diriba²,**

6 **Gutema Bulti¹, Tolawak Sura¹, Desta Ayana¹, Dawit Chala¹, Boki Lenjiso¹, Jaleta Bulti¹,**

7 **Saro Abdella¹, Habteyes Hailu Tola³**

81. HIV/AIDS disease research team, TB and HIV/AIDS Disease Research Directorate, Ethiopian

9 Public Health Institute, Addis Ababa, Ethiopia

102. Department of Medical Laboratory Sciences, College of Health Sciences, Addis Ababa

11 University, Ethiopia

123. TB disease research team, TB and HIV/AIDS Disease Research Directorate, Ethiopian Public

13 Health Institute, Addis Ababa, Ethiopia

14 **Address of the corresponding author**

15 Dereje Leta, P.o.Box 1242 Tell +251913974497, Fax +2512758634[office], Email

16 letadereje2@gmail.com

17 E-mail address co-authors

18 GG:gadissagutema@gmail.com, GGH: kodus12@gmail.com RD: regedire@gmail.com,

19 GB:gutebdi@gmail.com, TS:tolewaks9@gmail.com, DA:destaayana185@gmail.com, DC:

20 dawitchala2016@gmail.com, BL: bokilenjiso@gmail.com, JB: jaletatura@gmail.com, SA:

21 helen_saro@yahoo.com HT:habetola@gmail.com

22 **Abstract**

23 The outbreak of the severe acute respiratory syndrome coronavirus - 2 has quickly turned into a
24 global pandemic. Real-time reverse transcription Polymerase chain reaction is commonly used to
25 diagnose as “gold standard”. Many coronaviruses are sensitive to heat and chemicals. Heat and
26 chemical inactivation of samples is considered a possible method to reduce the risk of
27 transmission, but the effect of heating and chemical treatment on the measurement of the virus is
28 still unclear. Thus, this study aimed to investigate the effect of heat inactivation and chemical
29 bulklysis on virus detection. The laboratory-based experimental study design was conducted in
30 Ethiopian Public Health Institute from August to November 2020 on the samples referred to the
31 laboratory for Coronavirus disease-19 testing. Tests were performed on eighty
32 Nasopharyngeal/Oropharyngeal swab samples using the Abbott Real-time severe acute
33 respiratory syndrome coronavirus - 2 assays, a test for the qualitative detection of virus in the
34 sample. Data were analyzed and described by mean and standard deviation. Repeated
35 measurement analysis of variance was used to assess the mean difference between the three
36 temperatures and bulk lysis on viral detection. Post-hock analysis was employed to locate the
37 place of significant differences. P-values less than 0.05 was used to declare statistical
38 significance. About 6.2% (5/80) of samples were changed to negative results in heat inactivation
39 at 60°C and 8.7% (7/80) of samples were changed to negative in heat inactivation at 100°C. The
40 Cyclic threshold values of heat-inactivated samples (at 60°C, at 100°C, and bulk lysis) were
41 significantly different from the temperature at 56°C. The efficacy of heat-inactivation varies
42 greatly depending on temperature and duration. Therefore, local validation and verification of
43 heat-inactivation are essential.

44 **Keywords:** Heat inactivation, SARS-COV-2, RT- PCR, Ct value, Bulklysis

45 **Introduction**

46 Coronavirus disease 2019 (COVID-19) is a newly emerged human infectious disease caused by
47 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1). SARS-COV-2 is a group
48 IV-positive-sense, single-stranded Ribonucleic acid (ssRNA). Based on the rapid rate of increase
49 in humans, the World Health Organization (WHO) classified the COVID-19 outbreak as a
50 pandemic by the end of 2019 [1, 2]. SARS-CoV-2 infection is associated with COVID-19, which
51 is characterized by severe respiratory distress, fever, and cough and high rates of mortality,
52 especially in the elderly and those with underlying medical conditions [3]. Ethiopia is one of the
53 220 COVID-19 affected countries and territories, the first confirmed COVID-19 was reported on
54 March 13, 2020, and the first wave peak of kurtosis of the epidemic was from August to
55 September 2020. Since it has reached a critical point in March 2020, WHO declared that the
56 world needs speedy and quick solutions to diagnose and tackle the further spread of COVID-19
57 [4, 5]. Amplification of the viral RNA by qualitative and quantitative real-time polymerase chain
58 reaction (RT-PCR) is currently the gold standard procedure for diagnosis [1]. Molecular
59 modeling studies demonstrate that, like SARS-COV, SARS-COV-2 is a membrane-bounded
60 lipid bilayer containing a structural (M) and an envelope (E) membrane. This layer contains
61 spike (S) glycoprotein that gives this virus family the characteristic “crown” shape [6, 7].

62 The SARS-CoV-2 RNA polymerase, E gene that codes for an envelope, nucleocapsid region,
63 and the open reading frame (ORF) 1 are the most ideal amplification target. The N gene-based
64 rRT-PCR assay was more sensitive than the ORF 1 assay for the detection of SARS-CoV-2 in
65 clinical specimens [6]. The CDC rRT-PCR panel for detection of SARS-CoV-2 demonstrated
66 high sensitivity and specificity for detecting RNA copies/reaction with no observed false-
67 positive reaction [8], and it facilitates rapid detection of SARS-CoV-2 infections in humans.

68 These assays have proven to be valuable for rapid laboratory diagnosis and support, clinical
69 management, and infection prevention and control of COVID-19 [9, 10].

70 Laboratory viral nucleic acid (NA) testing using RT-PCR assays is currently the “gold standard”
71 for the diagnosis of COVID-19. However, the requirements of complex instruments and
72 laboratory conditions, cumbersome experimental procedures, and longer detection times greatly
73 hindered its large-scale applicability [1, 11].

74 Direct SARS-CoV-2 diagnosis is based on RNA detection by RT-PCR from nasopharyngeal- or
75 throat-swab samples commonly containing high viral loads [4, 12]). Buffer-based NA extraction
76 methods to obtain high-quality NA has not been developed primarily for the inactivation of
77 infectious samples [13, 14]). Since extraction processes can produce aerosols, they must be
78 performed in a Class 2 biosafety cabinet. However, automated NA extraction is often performed
79 outside of the biosafety cabinet, which can lead to aerosol formation. To avoid this, a pre-
80 inactivation step under appropriate biosafety conditions is an absolute requirement [13, 15, 16].

81 Accordingly, the extraction of viral RNA requires the first step of lysis or heat inactivation of the
82 virus at different temperatures for different minutes [7, 17]. In our laboratory at the Ethiopian
83 Public Health Institute (EPHI), we usually do heat inactivation for 30 minutes at 56°C. Despite
84 the fact that a higher temperature takes a shorter period to lower infectivity [13], its impact on
85 SARS-COV-2 detection has not been thoroughly examined. Furthermore, evidence indicated that
86 infectivity of SARS-COV-2 is prevented after heating at various temperatures at different times.
87 This is because the heat has an effect on SARS CoV-2 membrane protein [17, 18]. Even though
88 it is known temperature influences the infectivity and virulence of the virus, still there is a lack of
89 understanding of the molecular-level changes that are taking place in the virus due to the
90 different heat and chemical conditions [19]. In addition, heat inactivation had a great impact on

91 the amount of detectable RNA, which may cause false-negative results, especially in weakly
92 positive cases [8].

93 Evidence has shown that a variety of commonly used disinfectants and laboratory inactivation
94 procedures can reduce viral viability [17, 20]. This is especially important for healthcare settings
95 including laboratories that require highly reliable inactivation methods to protect staff working
96 with COVID-19 patients and samples [21].

97 The systematic study of the heat inactivation efficiency of rRT-PCR is still under investigation
98 and validation remains to be studied and confirmed. Early detection has a significant impact on
99 the prevention and control of SARS-CoV-2 samples. It is critical to identify individuals and
100 facilitate the implementation of protective measures such as social distancing, quarantine, and
101 isolation that help to mitigate the spread of the virus in the community.

102 Since many coronaviruses are heat sensitive, inactivation by heating samples to different
103 temperatures prior to testing is considered a possible method to reduce the risk of transmission,
104 but the effect of heating at different temperatures and for different time periods on the
105 measurement of SARS-CoV-2 remains unclear. Thus, this study aims to evaluate the effect of
106 heat inactivation at different temperatures and times and to determine the effect of chemical
107 inactivation by bulk lysis on SARS-CoV-2 detection.

108 **Materials and Methods**

109 **Study area and design**

110 The laboratory-based experimental study design was conducted at EPHI National HIV Reference
111 laboratory from August to November 2020 on the samples referred to the laboratory for COVID-

112 19 testing. The National HIV reference laboratory is Ethiopia's largest COVID-19 testing center,
113 did perform COVID-19 testing since March 2019, and tested over 200,000 samples as of August
114 2020. The laboratory has a well-established quality system and is ISO 15189; 2012 accredited by
115 Ethiopian National Accreditation Organization for HIV Viral load testing and early infant
116 diagnosis. The study was conducted on all known SARS-CoV-2 samples with Known threshold
117 cycle (CT) values.

118 **Sample size determination and sampling method**

119 Eighty Nasopharyngeal/Oropharyngeal swab samples were selected and taken out from -80°C
120 storage. The samples were stored with a disposable specimen collector containing 3-4 ml Viral
121 Transport Media (VTM). These samples were collected between August 25/2020 to September
122 30/2020, from samples under investigation for SARS-CoV-2 and submitted to the EPHI,
123 National HIV reference laboratory for diagnostic testing.

124 Positive samples with known Ct value were selected by simple random sampling technique, from
125 9,520 positive samples within one month, which is obtained from 28.4% prevalence of Covid-19
126 in Ethiopia as of August 20/2020. About 2380 samples were done in one week, then dividing this
127 sample by 80 is 30, which was the interval number by which samples with known Ct values were
128 selected. The first sample was selected by the lottery method.

129 **Specimen collection and testing**

130 The nasopharyngeal/Oropharyngeal swab specimens were obtained according to CDC
131 guidelines. All samples were registered with unique identification numbers (Barcode). All
132 samples were tested with 2 controls (1 positive, 1 negative) when testing by reference method

133 (Abbott Real-time SARS-COV-2 (EUA). Fig. 1 depicts the overall experimental procedure
134 followed.

135 **Fig 1: Process of specimen testing**

136 **Experiment**

137 Tests were performed using the Abbott Real-time SARS-CoV-2 assay, a rRT-PCR test for the
138 qualitative detection of SARS-CoV-2 in Nasopharyngeal and oropharyngeal swabs. Dual target
139 assay for RNA-dependent RNA polymerase (RdRp) and N-genes detection of NAs from SARS-
140 CoV-2 was analyzed. The assay also includes an internal control to indicate proper extraction,
141 amplification, and detection. Results were reported as positive if the Ct value was <32, and
142 defined as negative if the Ct value was 32 or more, based upon the signal threshold determined
143 by the manufacturer [1].

144 The effects of heat treatment at different temperatures and durations and chemical inactivation
145 on the SARS-CoV-2 rRT-PCR Ct-value were evaluated. The samples were inactivated at
146 different temperatures in a water bath for different minutes (at 56°C for 30min, at 60°C for
147 30min, and at 100°C for 10min) and by chemical bulklysis. WHO recommends heat inactivation
148 at 56°C for 30min and Abbott real-time RT-PCR is the golden method recommended for
149 SARS-COV-2 detection and this temperature was the best for the viral inactivation [22-24].
150 After viral heat inactivation, NA extraction was done from 0.6 ml sample volume on the Abbott
151 *m2000SP* instrument by using the Abbott *mSample* Preparation System Deoxyribonucleic acid
152 (DNA) according to the manufacturer's recommendations [1]. On the other hand, Chemical
153 inactivation was performed to see the effect of bulk lysis on the SARS-CoV-2 rRT-PCR. For
154 chemical inactivation, bulk lysis was tested with the appropriate composition of sample and lysis

155 proportion. As all samples were incubated with bulk lysis buffer and it was compared to the
156 effect of heat inactivation methods. Each sample was incubated with the bulk lysis buffer at
157 room temperature for 30 min; then, the sample was extracted by Abbott *m2000SP* instrument.
158 After the extraction was completed, the samples of heat and chemical treated group was detected
159 by Abbott *m2000rt* (12). The viral RNA was extracted from 500 μ L of each sample, and the final
160 elute was with 200 μ L by using elution buffer [1, 22]. The amplification and detection of SARS-
161 CoV-2 RNA was performed by Abbott *m2000rt* instrument targeted to dual-target assay for the
162 RdRp and N genes [1]. The SARS-CoV-2 and internal control (IC) specific probes were each
163 labeled with a different fluorophore (FAMTM (Carboxyfluorescein), ROXTM, (Carboxy-X-
164 rhodamine), and VIC[®] P (Proprietary dye) for target and IC detection, thus allowing for
165 simultaneous detection of both amplified products. The test is a real-time RT-PCR test intended
166 for the qualitative detection of NA from the SARS-CoV-2 in upper respiratory specimens [1].

167 **Data quality assurance**

168 Samples were collected by well-trained professionals. All laboratory procedures were performed
169 as per the documented standard operating procedures and according to specific manufacturing
170 recommendations. Quality of each reagent like lot number, expiry date, storage conditions,
171 physical leak-proof, no breakages, etc was checked before the actual laboratory analysis.
172 Samples and reagents were stored at appropriate temperatures as indicated on the manufacturer
173 inserts. Data was double-checked manually for completeness before data entry. We have used a
174 respective recommended manufacturer protocol.

175 **Data Analysis**

176 Data was analyzed and described by mean and standard deviation (mean±SD). Normality was
177 assessed for the three temperature scenarios and bulk lysis, and they were violated normality.
178 However, after we transformed by natural logarithm all of them were normally distributed.
179 Repeated measurement analysis of variance was used to assess the mean difference between the
180 three temperatures and bulk lysis on viral detection. To identify the place of significant
181 difference post hoc analysis with modified Bonferroni correction was used.

182 **Results**

183 **Reverse transcriptase real time polymerase chain reaction results of** 184 **heat-inactivated samples at different temperatures and durations**

185 The effect of heat treatment at different temperatures and durations on the SARS-CoV-2 rRT-
186 PCR Ct-value was evaluated. All heat-inactivated samples at 56°C for 30min were tested
187 positive. The Ct values of RdRp were 4.37–31.03 CN (cyclic number) at 56°C for 30min, 3.68–
188 30.64 CN at 60°C for 30min, and 3.37–28.74 CN at 100°C for 10min. The Ct values of the
189 chemical bulklysis inactivated samples were from 3.62–27.74 CN except for those with weak
190 positive samples as shown below in [Table 1] which were turned to negative results, as compared
191 to the heat-inactivated samples at 56°C (WHO recommended Standard temperature for heat
192 inactivation of SARS-COV-2, the cut-off Ct value for Abbott m2000rt machine is 32). Heat
193 inactivation methods resulted in the reduction of positive SARS-CoV-2 samples to undetectable
194 levels, especially in weak positive samples. About 6.2% (5/80) of samples were changed to
195 negative results in heat inactivation at 60°C and 8.7% (7/80) of samples were changed to
196 negative in heat inactivation at 100°C. The heat inactivation at 100°C for 10 mins for those with

197 high Ct value (low viral load concentration (weak positive samples)) was changed to a negative.
 198 Comparison of heat inactivation of weakly positive samples at 56°C with heat inactivation at
 199 60°C, 100°C, and chemical bulklysis were summarized in percentage as shown below. [Table 1]
 200 Table 1. Cycle threshold values for RdRp measured from swab samples following heat
 201 treatments at different temperatures and chemical bulklysis EPHI, Ethiopia.

S. N	Ct value results			
	T1	T2	T3	Bulklysis
1	30.11 CN	Negative	Negative	Negative
2	31.03 CN	Negative	Negative	Negative
3	28.57 CN	Negative	Negative	Negative
4	27.13 CN	28.37 CN	Negative	27.74 CN
5	26.22 CN	30.64 CN	Negative	26.62 CN
6	29.65 CN	Negative	Negative	28.89 CN
7	30.54 CN	Negative	Negative	28.99 CN
%		6.2%	8.7%	3.7%

202 T1=Temperature at 56°C, T2=Temperature at 60°C, T3=Temperature at 100°C, CN=Cyclic
 203 number, Ct=Cyclic threshold

204 The Ct values of heat-inactivated samples (at 60°C, 100°C) and bulk lysis were significantly
 205 different from the temperature at 56°C (as compared to WHO heat inactivation standard
 206 temperature at 56°C) ($p=0.01$, $p=0.001$) and $p=0.02$ respectively. The place of significant
 207 difference was identified by using post hoc analysis with modified Bonferroni correction. [Table
 208 2]

209 Table 2. Mean difference of group with their confidence interval and p -value following heat
 210 inactivation at different temperatures and durations EPHI, Ethiopia.

Group	Groups	MD (95%CI)	P -value
T1	T1 vs T2	0.10(0.02–0.18)	0.01
	T1vs T3	0.15(0.10–0.24)	0.001
	T1 vs Bulk lysis	0.13(0.02–0.24)	0.02
T2	T2 vs T1	-0.1(-0.20–-0.02)	0.01
	T2 vs T3	0.05(-0.01–0.11)	0.16
	T2 vs Bulk lysis	0.03(-0.01–0.13)	0.999
T3	T3 vs T1	-0.15(-0.24–-0.1)	0.001
	T3 vs T2	-0.05(-0.11–0.01)	0.16
	T3 vs Bulk lysis	-0.02(-0.12–0.10)	0.999
Bulk lysis	T1	-0.13(-0.24–-0.20)	0.02
	T2	-0.03(-0.13–0.10)	0.999
	T3	0.02(-0.10–0.12)	0.999

211 MD=Mean in difference, CI=Confidence interval, T1=Temperature at 56°C, T2=Temperature at
 212 60°C, T3 =Temperature at 100°C.

213 **Heat inactivation by chemical bulk lysis**

214 All samples were incubated with chemical bulk lysis buffer, (as it was compared with AVL
215 buffer, AVL serves as the standard for the comparison of the diverse chemical inactivation
216 methods). The decline in the viral RNA quantity was observed in some of the samples treated
217 with chemical bulklysis, especially for those with high Ct values stored at room temperature for
218 30 mins. It was shown that 3.7% (3/80) of analyzed samples were turned to negative (from weak
219 positive samples). There were significant differences between the Ct values of bulklysis and heat
220 inactivation at 56°C for the RdRp genes (Repeated measure ANOVA; $P = 0.02$). Following the
221 comparison of bulk lysis to all other forms of inactivation used in this study, only heat-
222 inactivated at 56°C was significantly different from bulklysis inactivation for the RdRp genes.

223 The mean average Ct values of the heat-treated samples at different temperatures and chemical
224 bulklysis for different durations (at 56°C for 30 min, 60°C for 30 min, 100°C for 10 min, and
225 bulklysis) as shown below by bar (Fig 2).

226 **Fig 2: Mean cyclic threshold comparison between the three temperatures and bulklysis**
227 (The standard errors bar shows mean \pm SD): T1-Temperature1= at 56°C; T2-temperature 2= at
228 60°C and T3- temperature 3= at 100°C; SD-standard deviation).

229 **Discussion**

230 SARS-CoV-2 has been emerged in late 2019 in China and now is on the list of Public Health
231 Emergency of International Concern (PHEIC). Respiratory specimens have been used to
232 diagnose SARS-CoV-2 infection by Abbott rRT-PCR, and are regarded as the main detection

233 method and the gold standard. Following the rapid global spread of SARS-CoV-2 and the need
234 for universal testing, more and more individuals are exposed to non-inactivated virus samples,
235 thereby increasing the chances of occupational infection. The WHO and United States CDC have
236 released laboratory guidelines to mitigate the risk of exposure during diagnostic and research
237 procedures [25, 26, 27]. Despite recommendations for handling within contained biosafety
238 cabinets, individuals working with these samples are still required to handle potentially
239 infectious viruses at the initial steps of acquiring and preparing samples before testing, thereby
240 increasing the risk of exposure. Therefore, the continued need for COVID-19 testing worldwide
241 requires the utilization of simple and effective inactivation techniques.

242 It has been shown that in the SARS-CoV-2 swab sample, the amount of SARS-CoV-2 could be
243 reduced at 60°C for 30min and bulklysis, but still infectious. Only heating at a temperature of
244 100°C for 10min was able to inactivate it totally, high temperature with high duration [12].
245 However, we have been trying to demonstrate that it is possible to ensure the test integrity by
246 applying heat inactivation at several conditions. RT-PCR Ct values are defined as the number of
247 cycles of amplification required for the accumulated fluorescence (produced by target gene
248 amplification) to reach a threshold above the background. Ct values are therefore inversely
249 related to viral load; low Ct values indicate high viral loads and high Ct values indicate low virus
250 NA concentration in the sample. With regards to SARS-CoV-2, low Ct values from SARS-CoV-
251 2 samples have been reported to correlate with an increased probability of developing severe
252 disease and mortality [28]. In this study, the Ct value was significantly affected by heating at 60
253 °C and 100 °C for those with weak positive samples. This is in agreement with the studies of
254 Pastorino, (2020) [12]. Therefore, an increment in Ct value may lead to a reduction in RT-PCR
255 sensitivity that could have an impact on clinical diagnosis. The less notable increase in Ct value

256 observed when the virus was heated to 100 °C, could be attributed to the shorter heating time,
257 this is in line with the study by Zou *et al.*, 2020 [25]. Lower temperature heat treatment
258 combined with chemical inactivation, short-duration high-temperature heat-treatments, or
259 chemical inactivation alone may be more appropriate to preserve RNA integrity and maximize
260 PCR optimization for detection of SARS-COV-2 RNA from low-concentration SARS-COV-2
261 samples. Our results show significant variation in the effect of heat-treatment inactivation on the
262 SARS-CoV-2 detection. This emphasizes the importance of local validation of inactivation
263 methods and the need for consistency in inactivation protocols to ensure sufficient reduction in
264 virus concentration for the processing of clinical samples.

265 Weak positive samples may become false negatives in SARS-CoV-2 RT-PCR detection. Our
266 study also has shown that the heat-inactivated samples at 56°C were consistent with those in
267 heat-inactivated ones at 60°C, 100°C, and chemical bulk lysis for low CT value results, which
268 agrees with the study done by Pastorino, B., 2020 and Pan, Y., 2020 [12, 29]. Heating at 100□
269 for 10min would result in a false negative, which is consistent with that of heating at 92□ for
270 15min, the SARS-CoV-2 RNA copies in a sample were dropped significantly as the study done
271 by Zou *et al.*, 2020 and Burton, J., 2021[25, 30]. In fact, studies have suggested that the sample
272 cells shall die and rupture in the event of relatively high temperature and long durations, leading
273 to the release of a large number of cell nucleases, and then a large amount of RNA degradation,
274 which may contribute to false negatives in NA detection. We hypothesize that heating at 100□
275 for 30 min or 60 min (high temperature for a long time) lyse a large number of cells, and expose
276 RNA to RNases present in the samples, and the duration is also a key factor.

277 Although our study showed that heating at 100□ for 10min was consistent with heated one's at
278 56°C, especially for those with strong positive samples, except for those samples with weak

279 positive, strong positive samples were showed a tendency to decrease in Ct values to some
280 extent, this is in agreement with the study done by Wang, T., 2020 [31]. The RNA preservation
281 may be due to the preservation chemical, which contains guanidine isothiocyanate. This
282 suggested that the presence of the preservation chemical can effectively protect the integrity of
283 the viral nucleic acid, thereby increasing the proportion of detectable nucleic acids. It may also
284 be that we used the original samples rather than the diluted samples. However, many factors can
285 influence the effect of a lysis buffer, including the virus concentration, nature of sample matrix,
286 contact time and reaction temperature, virus structure, and concentration/composition of the lysis
287 buffer (denaturing agent and/or detergent, pH) used.

288 **Ethical Clearance**

289 Ethical clearance was obtained from EPHI Scientific ethical review committee. Approval and
290 official permission was obtained from the EPHI research committee to use the leftover samples
291 in the laboratory (EPHI-IRB-296-2020). The confidentiality of the data collected was kept to a
292 maximum and each patient identity was coded.

293 **Limitation of the study**

294 Performance has only been established with the specimen types listed in the Intended Use. Other
295 specimen types have not been evaluated and should not be used with this assay.

296 The small sample size can affect the conclusion.

297 Since our study conducted analysis from stored positive samples, weak positive samples may be
298 affected by repeated thaw and refreezing.

299 **Conclusion and Recommendations**

300 We found that the effect of heat-inactivation varies greatly depending on temperature and
301 duration. The impact of chosen inactivation method on the sensitivity of subsequent SARS-CoV-
302 2 detection should be assessed locally. The effect of heat on Ct value should be considered when
303 interpreting diagnostic PCR results from clinical samples which could have an initial low virus
304 concentration. Since high temperature and chemical bulklysis have the tendency to release a
305 large number of RNA and used it for sequencing purposes (preserve and optimize). Our findings
306 need to be further verified by other large-scale research and virus infectivity experiments

307 **List of Abbreviations**

308 CDC: Center Disease Control and Prevention; CT: Cyclic Threshold; CN: Cyclic Number; DNA:
309 Deoxyribose nucleic acid; EPHI: Ethiopian Public Health Institute; EUA: Emergency Use
310 Authorization; IC: Internal control; ISO: International Standard for Organization; SARS-COV-2:
311 Severe Acute Respiratory Syndrome Coronavirus 2; RNA: Ribonucleic acid; WHO: World
312 Health Organization; RT-PCR: Real-time Polymerase Chain Reaction; RdRp: RNA dependent
313 RNA polymerase; VTM: Viral Transport Media

314 **Facilities available for the study**

315 The study was conducted in the Ethiopian public health institute. We were also, using suitable
316 data storage devices and a recent version of statistical packages that are available at EPHI for
317 data storage and analysis.

318 **Declaration of Conflict of Interest**

319 We declare that we have no conflict of interest.

320 **Authors' contributions**

321 DL has participated in the design, coordination of the study, and data collection, analysis, and
322 interpretation. GG has contributed in, drafting, revising, or critically reviewing the article and
323 revision and amendment of the draft manuscript. GGH has contributed in wright up, analysis and
324 review, RD has contributed in wright up, analysis, and review, GB has contributed in data
325 collection and analysis, TS has contributed in data collection and analysis, DA has contributed in
326 data collection and analysis, DC has contributed in data collection, analysis, and manuscript
327 preparation, BL has contributed in wright up, analysis and review, JB has contributed to
328 conceptualization and methodology, SA has contributed to conceptualization and writeup, HHT
329 has contributed to the design, including final approval of the version to be published. All authors
330 read and approved the final manuscript.

331 **Acknowledgments**

332 We are grateful in extending our thanks to Ethiopian Public Health Institute for allowing as the
333 setup, ethically approve our research and allow as to use the leftover samples. We also extend
334 our appreciation to Mr. Atsbeha G/eigziebxier for his unreserved contribution.

335 **References**

3361. Abbott Molecular. Abbott Real-Time SARS-COV-2. Abbott Real-Time SARS-CoV-2
337 Emergency Use Authorization Package 236 Insert, REF 09N77-095, 51-608445/R1. 2020;
338 Abbott Molecular Inc., Des Plaines, IL.
3392. Kratzel A, Todt D, V'kovski P, Steiner S, Gultom M, Thao TT, *et al*. Inactivation of Severe
340 Acute Respiratory Syndrome Coronavirus-2 by WHO-Recommended Hand Rub Formulations

- 341 and Alcohols. *Emergency Infection Disease*. 2020;26(7): 1592-1595.doi:
342 10.3201/eid2607.200915.
3433. Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC, *et al*.
344 Diagnosing COVID-19: The disease and tools for detection. 2020;
345 doi: 10.1021/acsnano.0c02624.
3464. Gates B. Responding to Covid-19 - A Once-in-a-Century Pandemic? *New England Journal of*
347 *medicine*. 2020;323(16):2019-20.
3485. World meter. Countries where Coronavirus has spread - World meter (2020).
3496. Case JB, Bailey AL, Kim AS, Chen RE, and Diamond MS. Growth, detection, quantification,
350 and inactivation of SARS-CoV-2. *Journal of virology*. 2020; DOI: 10.1016/j.virol.2020.05.015
3517. Lalmuanawma S, Hussain J, and Chhakchhuak L. Applications of machine learning and artificial
352 intelligence for Covid-19 (SARS-CoV-2) pandemic. *Chaos Solitons Fractals*. 2020;139.
353 DOI: 10.1016/j.chaos.2020.110059.
3548. World Health Organization. Laboratory testing strategy recommendations for COVID-19.
355 Evaluation of Chemical Protocols for Inactivating SARS-CoV-2 Infectious Samples. 2020: 6.
3569. Ngo KA, Jones SA, Church TM. Unreliable Inactivation of Viruses by Commonly Used Lysis
357 Buffers. *Applied Biosafety*.2017; 22(2):56-9.
35810. World Health Organization. Risk-based classification of diagnostics for WHO prequalification of
359 Diagnostics. 2014: 1-18.
36011. D'Cruz RJ, Currier AW, and Sampson VB. Laboratory Testing Methods for Novel Severe Acute
361 Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). *Cell Development Biology*.
362 2020;<https://doi.org/10.3389/fcell.2020.004686>.

36312. Pastorino B, Touret F, Gilles M, Luciani L, Lamballerie X and Charrel RN. Evaluation of
364 chemical protocols for inactivating SARS-COV-2 infectious samples. 2020;12(6): 624.
365 <https://doi.org/10.3390/v12060624>.
36613. Kumar M, Mazur S, Ork BL, Postnikova E, Hensley LE, Jahrling PB, *et al.* Inactivation and
367 safety testing of Middle East Respiratory Syndrome Corona virus, *Journal of Virological*
368 *Methods*. 2015;223: 13-18.
36914. Seo G, Lee G, Kim MJ, Baek S, Choi M, Ku KB, *et al.* Rapid Detection of COVID-19
370 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens. 2020;
371 doi: 10.1021/acsnano.0c02823.
37215. Africa CDC. Africa Joint Continental Strategy for COVID-19 outbreak.
37316. WHO-COVID-19-lab-testing-2020. (Internet). sur:
374 [https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab-testing-2020.1-](https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab-testing-2020.1-eng.pdf)
375 [eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab-testing-2020.1-eng.pdf).
37617. Chan KH, MalikPeiris JS, Lam SY, Poon LLM, Yuen KY, and Seto WH. The effects of
377 temperature and relative humidity on the viability of the SARS Coronavirus. *Advances in*
378 *Virology*. 2011; <https://doi.org/10.1155/2011/734690>.
37918. Kampf G, Voss A, and Scheithauer S. Inactivation of corona virus by heat. *Journal of hospital*
380 *infection*. 2020;105(2): 348-349.
38119. Rath SL and t Kumar K. Investigation of the Effect of Temperature on the Structure of SARS-
382 CoV-2 Spike Protein by Molecular Dynamics Simulations. *Front Molecular Biosciences*.
383 2020; <https://doi.org/10.3389/fmolb.2020.583523>

38420. Chan KH, Sridhar S, Zhang RR, Chu H, Fung AY-F, Chan G, *et al.* Factors affecting stability
385 and infectivity of SARS-CoV-2. *Journal of Hospital Infection.* 2020;
386 <https://doi.org/10.1016/j.jhin.2020.07.009>
38721. Paper O, Umaru FA, States U, States U, Umaru F. Scaling up testing for COVID-19 in Africa:
388 Responding to the pandemic in ways that strengthen health systems. *Africa Journal Lab Med.*
389 2020;9(1):19-20.
39022. Chen H, Wu R, Xing Y, Du Q, Xue Z, Xi Y, *et al.* Influence of Different Inactivation Methods
391 on Severe Acute Respiratory Syndrome Corona virus 2 RNA Copy Number. *Journal of clinical*
392 *microbiology.* 2020; DOI: 10.1128/JCM.00958-20.
39323. Hu X, An T, Situ B, Hu Y, Ou Z, Li Q, *et al.* Heat inactivation of serum interferes with the
394 immunoanalysis of antibodies to SARS-CoV-2. *Journal of Clinical Laboratory Analysis.* 2020;
395 doi: <https://doi.org/10.1101/2020.03.12.20034231>
39624. Lu X, Wang L, Sakthivel SK, Whitaker B, Murray J, Kamili S, *et al.* Real-Time Reverse
397 Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Corona virus 2.
398 2020;26 (8). doi: <https://doi.org/10.1101/2020.05.19.20101469>
39925. Zou J, Zhi S, Chen M, Su X, Kang L, Li C, *et al.* Heat inactivation decreases the qualitative real-
400 time RT-PCR detection rates of clinical samples with high cycle threshold values in COVID-
401 19. *Diagnostic Microbiology of Infection Disease.*2020; (98) 115109-115109. [Google Scholar]
40226. World Health Organization. Laboratory testing for coronavirus disease 2019 (COVID-19) in
403 suspected human cases: interim guidance. 2020.
40427. United States Centers for Disease Control and Prevention. Interim laboratory biosafety
405 guidelines for handling and processing specimens associated with coronavirus disease 2019
406 (COVID-19). 2020.

40728. Rao SN, Manissero D, Steele VR, & Pareja J. A systematic review of the clinical utility of cycle
408 threshold values in the context of COVID-19. *Infection of Disease Therapy*. 2020; 9:573-586.
409 [Google Scholar]
41029. Pan Y, Long L, Zhang D, Yan T, Cui S, Yang P, *et al*. Potential false-negative nucleic acid
411 testing results for severe acute respiratory syndrome coronavirus 2 from thermal inactivation of
412 samples with low viral loads. *Journal of Clinical Chemistry*. 2020; 66(6):794-801. doi:
413 10.1093/clinchem/hvaa091. [Google Scholar]
41430. Burton J, Love H, Richards K, Burton C, Summers S, Pitman J, *et al*. The effect of heat-
415 treatment on SARS-CoV-2 viability and detection. *Journal of virological methods*. 2021;290,
416 114087. <https://doi.org/10.1016/j.jviromet.2021.114087>
41731. Wang T, Lien C, Liu S, & Selvaraj P. Effective Heat Inactivation of SARS-CoV-2. 2020;
418 medRxiv. doi: <https://doi.org/10.1101/2020.04.29.20085498> [Google Scholar].

419 **Supporting Information**

420 S1 Fig 1: Process of specimen testing

421 S2 Fig2: Mean cyclic threshold comparison between the three temperatures and bulklysis

422 S1 Table1: Cycle threshold values for RdRp measured from swab samples following heat
423 treatments at different temperatures and chemical bulklysis.

424 S2 Table2: Mean difference of group with their confidence interval and p-value following heat
425 inactivation at different temperatures and durations.




Fig 1: Process of specimen testing

